Historic Breakthrough in GIST Treatment: Cogent’s Bezuclastinib Combination Poised to Become New Standard of Care
Cogent Biosciences announced "transformative" success with their experimental drug, bezuclastinib, in combination with sunitinib, significantly delaying disease progression in patients battling advanced GIST (a form of stomach cancer).
